-
Sector Analysis
Nontuberculous Mycobacteria (NTM) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033
The report provides an assessment of the NTM therapeutics market including disease overview, epidemiology, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, and market outlook. NTM refers to infection with a group of bacteria within the Mycobacterium genus, which excludes Mycobacterium tuberculosis (tuberculosis) and Mycobacterium leprae (leprosy). NTM infections are noncontagious, opportunistic infections that cause a wide range of clinical disease in patients with pre-existing health conditions or compromised immune systems. ). In terms of global burden,...
-
Sector Analysis
Metabolic Dysfunction-Associated Steatohepatitis (MASH): Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032
This report covers the 7 major markets and provides an Excel-based forecast model for the Metabolic Dysfunction-Associated Steatohepatitis (MASH) market through 2032. GlobalData estimated that drug sales for MASH in 2022 were approximately $802.3 million across the 7MM, with the market size anticipated to grow to approximately $20.3 billion by 2032, at a compound annual growth rate (CAGR) of 38.2%. Major drivers of growth during the forecast period include the anticipated launch of several pipeline agents including those within the...
-
Thematic Analysis
FDI Trends in Africa (2025)
Overall, Africa’s share of global FDI remains small, however, investment opportunities across the continent are increasingly viewed as a growth frontier, presenting competitive long-term benefits. Notably, Africa continues to offer higher average profitability on FDI relative to other regions, despite ample structural deficiencies fueling a high-risk premium; this is supported by the fact that the largest 40 companies in Africa have annualized returns of 12.9% in the last year. GlobalData’s FDI Team expects FDI to diversifyaway from traditional, extractive industries...
-
Sector Analysis
Multiple Sclerosis Epidemiology Analysis and Forecast to 2034
Multiple sclerosis (MS) is an autoimmune disease affecting principally the central nervous system that causes nerve sheath demyelination, followed by axon damage and paralysis. MS symptoms include muscle weakness, weak reflexes, tremors, muscle spasms, prolonged double vision, slurred speech, and balance problems. MS can occur at any age, but commonly affects people aged 15–60 years. The diagnosis of MS depends upon patients’ symptoms, magnetic resonance imaging (MRI), and laboratory results, but it is mostly diagnosed in the late phases. Presently,...
-
Sector Analysis
Pulmonary Arterial Hypertension (PAH) Epidemiology Analysis and Forecast to 2034
Pulmonary arterial hypertension (PAH) is a rare, progressive disorder of unknown cause, characterized by vascular proliferation and remodelling of the small pulmonary arteries. A significant number of risk factors and pathophysiological conditions are suspected to play roles in disease progression (Humbert et al., 2004, 2010; Simonneau et al., 2004; Bonnet et al., 2017). In PAH, blood vessels in the lungs are narrowed, blocked, or destroyed. The damage slows blood flow through the lungs and can lead to right ventricular overload...
-
Thematic Analysis
Outsourcing in Clinical Trials (OCT) Europe: Barcelona, Spain 29-30 April 2025
The Outsourcing in Clinical Trials Europe 2025 conference took place in Barcelona, Spain, April 29–30. The meeting provided an opportunity for clinicians, pharmaceutical company executives, trial software vendors, technology experts, and contract research and manufacturing organization executives to discuss the latest trends and challenges in the clinical trials space in Europe. In this report, GlobalData provides expert insights into key themes relevant to the clinical trials sector, with a focus on elements that drive successful operations in Europe. Through several...
-
Sector Analysis
Mucopolysaccharidosis II (Hunter Syndrome) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Mucopolysaccharidosis II (Hunter Syndrome) Therapeutics. In 2024 and 2029, India is anticipated to have the highest number of diagnosed prevalent cases of MPS II, representing a large portion of global cases. Currently, the MPS II market has only three FDA-approved innovator drugs available to treat MPS II. The MPS II pipeline holds 15 molecules, with only two assets in the pre-registration stage, three assets in Phase...
-
Sector Analysis
Mucopolysaccharidosis III (Sanfilippo Syndrome) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Mucopolysaccharidosis III (Sanfilippo Syndrome) Therapeutics. In 2024 and 2029, India is anticipated to have the highest number of diagnosed prevalent cases of MPS III, representing a large portion of global cases. Currently, there is no cure for MPS III, and no disease-modifying therapies are available. The MPS III pipeline holds 24 molecules, with only one asset in the pre-registration stage. Over the past decade, 29 clinical...
-
Sector Analysis
Endometriosis Epidemiology Analysis and Forecast to 2034
Endometriosis is a chronic disease, and is defined as the presence of functional endometrial mucosa outside the uterine cavity, often in the pelvis, but also more rarely in locations such as the pericardium, pleura cavity, and even in the brain tissue (World Health Organization, 2025). It is one of the most common benign gynecological diseases in pre-menopausal women, and affects roughly 10–15% of reproductive age women and girls globally (World Health Organization, 2025). Normally, endometrial tissue or endometrium forms the...
-
Product Insights
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Global Clinical Trials Review, 2025" provides an overview of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Clinical trials scenario. This report provides top line data relating to the clinical trials on Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.